Figure 1.

Schematic illustration of a combination of irreversible electroporation (IRE) with STING agonists for effective cancer immunotherapy. IRE induces immunogenic cell death (ICD) of cancer cells, leading to the release of tumor antigens and the expression of damage-associated molecular patterns (DAMPs). Additionally, intratumoral injection of STING agonists induces maturation of antigen-presenting cells (APCs), triggering the activity of cytotoxic lymphocytes. As a result, the combination of IRE and STING agonists can effectively induce anti-tumor immune responses.